I don’t believe there is an R/S on the table according to the language in the 8K/A. Been looking at it tonight.
2016 10-K; Name Change; Reverse Split. Immediately following the Closing, the Seller shall take all actions necessary and/or required by applicable law, rule and/or regulation including, but not limited to, those of FINRA, the OTC Markets, DTC and the SEC to (i) ensure the 2016 10-K is filed with the SEC on a timely basis, (ii) effectuate a reverse stock split of the issued and outstanding shares of Common Stock, on such ratio as determined by the Board of Directors of the Company following the Closing (the “ Reverse Split ”), and (iii) to change the name of the Company to that so determined by the Company following the Closing.
"the Seller shall take all actions"
The seller in this transaction is Kistler.
Change of control was filed with Florida SOS April 4, with the 10K for year ending 2016 filed by Kistler on the April 5.
Redman is listed as CEO now with the Florida SOS. It is no longer possible for Kistler (the seller) to initiate a reverse split as described in the 8K/A.
As I see it, the BOD decided against a R/S at closing.
If the officers of Oncolix wish to initiate a R/S in the future, there should be a PRE-14C filed with the SEC at a later date.
IMO and FWIW.
